81 related articles for article (PubMed ID: 16028404)
1. [Immunohistochemical analysis of epidermal growth factor receptors expression in malignant ovarian tumors].
Tomov S; Popovska S; Veselinova T; Gorchev G; Velkova A
Akush Ginekol (Sofiia); 2005; 44 Suppl 2():42-7. PubMed ID: 16028404
[TBL] [Abstract][Full Text] [Related]
2. [Determination of epidermal growth factor receptor expression in malignant ovarian tumors using radioligand assay].
Tomov S; Tsingilev D; Gorchev G; Velkova A
Akush Ginekol (Sofiia); 2004; 43(2):37-40. PubMed ID: 15185528
[TBL] [Abstract][Full Text] [Related]
3. Expression of metastasis-related nm23-H1 and nm23-H2 genes in ovarian carcinomas: correlation with clinicopathology, EGFR, c-erbB-2, and c-erbB-3 genes, and sex steroid receptor expression.
Mandai M; Konishi I; Koshiyama M; Mori T; Arao S; Tashiro H; Okamura H; Nomura H; Hiai H; Fukumoto M
Cancer Res; 1994 Apr; 54(7):1825-30. PubMed ID: 7907945
[TBL] [Abstract][Full Text] [Related]
4. [Expression of epidermal growth factor receptors in benign ovarian tumors].
Tomov S; Tsingilev D; Gorchev G; Velkova A; Veselinova T
Akush Ginekol (Sofiia); 2004; 43(4):13-7. PubMed ID: 15318536
[TBL] [Abstract][Full Text] [Related]
5. EGFR, HER2÷neu and Ki67 immunoexpression in serous ovarian tumors.
Marinaş MC; Mogoş G; Ciurea R; Mogoş DG
Rom J Morphol Embryol; 2012; 53(3):563-7. PubMed ID: 22990547
[TBL] [Abstract][Full Text] [Related]
6. A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
Skírnisdóttir I; Seidal T; Sorbe B
Int J Gynecol Cancer; 2004; 14(2):259-70. PubMed ID: 15086725
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Schilder RJ; Sill MW; Chen X; Darcy KM; Decesare SL; Lewandowski G; Lee RB; Arciero CA; Wu H; Godwin AK
Clin Cancer Res; 2005 Aug; 11(15):5539-48. PubMed ID: 16061871
[TBL] [Abstract][Full Text] [Related]
8. p14 expression differences in ovarian benign, borderline and malignant epithelial tumors.
Cabral VD; Cerski MR; Sa Brito IT; Kliemann LM
J Ovarian Res; 2016 Oct; 9(1):69. PubMed ID: 27770808
[TBL] [Abstract][Full Text] [Related]
9. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
10. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study.
Leibl S; Bodo K; Gogg-Kammerer M; Hrzenjak A; Petru E; Winter R; Denk H; Moinfar F
Gynecol Oncol; 2006 Apr; 101(1):18-23. PubMed ID: 16330088
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro.
Morishige K; Kurachi H; Amemiya K; Fujita Y; Yamamoto T; Miyake A; Tanizawa O
Cancer Res; 1991 Oct; 51(19):5322-8. PubMed ID: 1717146
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemical studies on epidermal growth factor receptor (EGF-R) in gynecological malignant tumor].
Furugen Y
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Apr; 43(4):410-6. PubMed ID: 2066613
[TBL] [Abstract][Full Text] [Related]
13. A comparison of biochemical and immunohistochemical assessment of EGFR expression in ovarian cancer.
Owens OJ; Stewart C; Leake RE; McNicol AM
Anticancer Res; 1992; 12(5):1455-8. PubMed ID: 1444207
[TBL] [Abstract][Full Text] [Related]
14. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
15. Tissue microarray analysis of EGFR and erbB2 copy number changes in ovarian tumors.
Dimova I; Zaharieva B; Raitcheva S; Dimitrov R; Doganov N; Toncheva D
Int J Gynecol Cancer; 2006; 16(1):145-51. PubMed ID: 16445625
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical assessment of proliferation markers and altered gene expression in archival specimens of ovarian epithelial tumors.
Khalifa MA; Lacher DA; Lage JM; Mannel RS; Walker JL; Angros LH; Min KW
Cancer Detect Prev; 1997; 21(6):532-9. PubMed ID: 9398993
[TBL] [Abstract][Full Text] [Related]
17. [Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer].
Zhang J; Chen AP; Wang B; Zhao SP; Liu LZ; Dai SZ
Ai Zheng; 2008 Dec; 27(12):1331-6. PubMed ID: 19080004
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of KI67, p53, human epithelial growth factor receptor 2, topoisomerase IIalpha, epidermal growth factor receptor, and nm23 expression of ovarian carcinomas and disseminated tumor cells in the bone marrow.
Schindlbeck C; Hantschmann P; Zerzer M; Jahns B; Rjosk D; Janni W; Rack B; Sommer H; Friese K
Int J Gynecol Cancer; 2007; 17(5):1047-55. PubMed ID: 17433065
[TBL] [Abstract][Full Text] [Related]
19. Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma.
Hedner C; Borg D; Nodin B; Karnevi E; Jirström K; Eberhard J
PLoS One; 2016; 11(2):e0148101. PubMed ID: 26844548
[TBL] [Abstract][Full Text] [Related]
20. Expression of apoptosis-related proteins in endometriomas and benign and malignant ovarian tumours.
Fauvet R; Poncelet C; Hugol D; Lavaur A; Feldmann G; Daraï E
Virchows Arch; 2003 Jul; 443(1):38-43. PubMed ID: 12756564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
